Antibody-drug conjugates: Effective and promising "magic bullets" ADCs are among the most promising drug classes in oncology, currently, with the development accelerating in the last 20 years. An ADC is composed of a monoclonal antibody and a cytotoxic payload connected with a linker to create a targeted immunoconjugate . Despite being proposed in the early 1900s by Paul Ehrlich as a "magic bullet" that targets pathogens, 105 it was not until the 1980s that ADCs were first explored in clinical trials with the first ADC gaining US FDA approval in the year 2000.